Aclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Aclarion, Inc. (Nasdaq: ACON) said the USPTO issued a Notice of Allowance for a patent application covering “Multi-Voxel Prescription for Lumbar Disc Evaluation,” aimed at improving MR spectroscopy voxel positioning in its Nociscan workflow. The company said the claims are intended to reduce repeat scans and variability across sites, extending its IP portfolio of 65+ patents worldwide.
How this was made
The 30-second read
Why it matters
The USPTO Notice of Allowance covers scan-prescription methods to improve voxel placement accuracy, aiming to reduce trial-and-error, repeat scans, and variability across imaging sites.
Market read
This is a tangible IP milestone for Aclarion’s MR spectroscopy scan-prescription workflow, but the release does not quantify financial impact or adoption changes.
What to watch
Investors may discount the news if Nociscan adoption metrics, reimbursement, or competitive differentiation are unchanged; the release also lacks details on expected timeline to issuance or enforcement strategy.
Background
Aclarion’s Nociscan is a SaaS platform using MR spectroscopy and analytics to help localize chronic low back pain discs.
Ticker impact
Aclarion announced USPTO issued a Notice of Allowance for a patent covering multi-voxel prescription for lumbar disc MR spectroscopy in Nociscan.
Near-term impact likely modest unless investors view it as a meaningful step toward commercialization scale or licensing leverage.
The disclosure is a concrete regulatory milestone (Notice of Allowance), but it does not include financial terms, revenue impact, or issuance timing beyond “once issued.”
Market effects
Highlights defensibility in MR spectroscopy workflow software, which may support investor appetite for imaging AI platforms with IP-protected acquisition pipelines.
No clear regional read-through beyond US-listed healthcare tech sentiment.
Limited global impact; patent coverage is described as worldwide (issued and pending), but no international commercialization update is provided.
Counterpoint
A Notice of Allowance is not the same as an issued patent, and the article provides no evidence of near-term revenue uplift from the claim scope.
Key entities
- companyAclarion, Inc.
Nasdaq-listed healthcare technology company marketing Nociscan and building IP around MR spectroscopy acquisition and analytics.
- regulatorUSPTO
US Patent and Trademark Office that issued the Notice of Allowance for Aclarion’s patent application.
- productNociscan
Aclarion’s MR spectroscopy-based SaaS workflow for lumbar disc evaluation.
